Kanamycin in the therapy of pulmonary tuberculosis in the United States.
D000636:Aminosalicylic Acids / Q000494:pharmacology; D000995:Antitubercular Agents / Q000494:pharmacology; D003523:Cycloserine / Q000494:pharmacology; D005000:Ethionamide / Q000494:pharmacology; D006801:Humans; D007538:Isoniazid / Q000494:pharmacology; D007612:Kanamycin / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D009169:Mycobacterium tuberculosis / Q000187:drug effects; D010670:Phenylthiourea / Q000031:analogs & derivatives / Q000494:pharmacology; D011718:Pyrazinamide / Q000494:pharmacology; D013307:Streptomycin / Q000494:pharmacology; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*; D014481:United States; D000159:Vestibulocochlear Nerve / Q000187:drug effects
D000636:Aminosalicylic Acids; D000995:Antitubercular Agents; D011718:Pyrazinamide; D007612:Kanamycin; D010670:Phenylthiourea; D003523:Cycloserine; D005000:Ethionamide; D007538:Isoniazid; D013307:Streptomycin